 When activated DCs that carry variants of recombinant SeV are administered, survival of animals injected with malignant melanoma, colorectal cancer, squamous cell carcinoma, hepatic cancer, neuroblastoma, and prostate cancer is significantly improved.It has been shown that the administration of such DCs prior to tumor cell injection prevents metastasis of neuroblastoma and prostate adenocarcinoma to the lungs.SeV can replicate to high titers in human monocyte-derived DCs.